Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease
Shots:
- Teva to get an exclusive license globally to develop, manufacture & commercialize anle138b &sery433. Additionally, both companies will jointly develop the products for MSA & PD based on early-stage clinical studies & will investigate additional indications based on clinical outcomes
- The P-I study of anle138b demonstrated a favorable benefit-risk profile at all doses while achieving higher plasma levels than those required for full therapeutic efficacy in animal models
- Modag's Anle138b has been initially developed for MSA & PD & is designed to facilitate other ND disorders such as AD. Anle138b is currently being evaluated in a P-Ib clinical trial for the patient with PD
| Ref: Teva | Image: Biospace
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com